Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 12 mechanisms across 130 industry trials with a known mechanism of action.

See full pipeline →

Janus Kinase Inhibitor

14 trials 1 active 2 sponsors

Selective T Cell Costimulation Modulator

13 trials 1 active 3 sponsors

TNF

10 trials 1 active 4 sponsors

CD20-directed Cytolytic Antibody

6 trials 1 active 6 sponsors

Tumor Necrosis Factor Blocker

36 trials 21 sponsors

Interleukin-6 Receptor Antagonist

33 trials 4 sponsors

Folate Analog Metabolic Inhibitor

9 trials 3 sponsors

Calcineurin/FKBP-12

4 trials 2 sponsors

Interleukin-17 Receptor A Antagonist

2 trials 1 sponsor

Corticosteroid

1 trials 1 sponsor

Purine Antimetabolite

1 trials 1 sponsor

Interleukin-17A Antagonist

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

705 industry-sponsored trials across 220 sponsors

View full landscape →

Showing 60 of 60 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Eisai Korea Inc.	Filgotinib Maleate	—	COMPLETED	2026-01-21	NCT06625242
Eli Lilly	Baricitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2025-05-28	NCT03915964
Eli Lilly	Baricitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2025-05-19	NCT04086745
Astellas Pharma Korea, Inc.	tacrolimus	Calcineurin/FKBP-12	COMPLETED	2020-06-16	NCT03737708
Sanofi	SARILUMAB	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2019-07-31	NCT03449758
Bristol-Myers Squibb	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2019-03-28	NCT02557100
Pfizer	CP-690,550	—	COMPLETED	2018-11-19	NCT02831855
AbbVie	Adalimumab	TNF	COMPLETED	2018-05-03	NCT02198651
Roche	Prednisone	Corticosteroid [EPC]	COMPLETED	2018-02-09	NCT02573012
Dong-A ST Co., Ltd.	CELBESTA®	—	COMPLETED	2017-12-26	NCT02780323
Bristol-Myers Squibb	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2016-12-26	NCT01758198
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2016-07-29	NCT02682823
Roche	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-03-25	NCT01331837
UCB Pharma SA	Certolizumab Pegol (CZP)	—	COMPLETED	2015-11	NCT01500278
Jiangsu Simcere Pharmaceutical Co., Ltd.	Iguratimod	—	COMPLETED	2015-08	NCT01554917
AbbVie (prior sponsor, Abbott)	adalimumab	TNF	COMPLETED	2015-07	NCT01162421
Chong Kun Dang Pharmaceutical	Tacrolimus with Methotrexate	—	COMPLETED	2015-06	NCT01746680
Astellas Pharma Inc	Tacrolimus	Calcineurin/FKBP-12	COMPLETED	2015-05-11	NCT01511003
UCB Italy s.p.a.	Certolizumab pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2015-05	NCT01443364
Mundipharma Korea Ltd	Lodotra®	—	COMPLETED	2015-04	NCT02072200
Pfizer	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2015-03	NCT01578850
Mundipharma Pte Ltd.	Buprenorphine transdermal patch	—	COMPLETED	2015-01	NCT01961271
Mundipharma Pharmaceuticals Sdn. Bhd.	Buprenorphine Transdermal Patch	—	COMPLETED	2015-01	NCT02519387
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2014-07	NCT01149057
Roche	methotrexate	Folate Analog Metabolic Inhibitor [EPC]	COMPLETED	2014-05	NCT01399697
Amgen	Etanercept via Autoinjector A	—	COMPLETED	2014-03-04	NCT01875991
Pfizer	Phase 1: Etanercept	—	COMPLETED	2013-04	NCT00848354
Roche	methylprednisolone	—	COMPLETED	2013-03	NCT01219933
Amgen	etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2013-02	NCT01313208
Roche	rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2013-01-06	NCT01382940
AbbVie (prior sponsor, Abbott)	Adalimumab	TNF	COMPLETED	2013-01	NCT01185288
Amgen	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2012-12	NCT00654368
UCB Pharma	Certolizumab Pegol (CZP)	—	COMPLETED	2012-10	NCT01255761
Pfizer	etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2012-06	NCT00913458
Pfizer	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2012-06	NCT00858780
Roche	rituximab [MabThera/Rituxan]	—	COMPLETED	2012-05-16	NCT01000610
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2012-03	NCT01195272
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2012-01	NCT01119859
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2011-12	NCT01089023
Roche	tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2011-12	NCT01163747
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2011-09	NCT01034397
Astellas Pharma Inc	Tacrolimus	Calcineurin/FKBP-12	COMPLETED	2011-06	NCT01224041
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2011-02-14	NCT00996203
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2010-07	NCT02010216
UCB Pharma	Certolizumab pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2010-06	NCT00993668
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2010-05	NCT01010503
Wyeth is now a wholly owned subsidiary of Pfizer	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2010-03	NCT00768053
Centocor Ortho Biotech Services, L.L.C.	Infliximab	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2010-01	NCT00714493
Astellas Pharma Inc	Tacrolimus	Calcineurin/FKBP-12	COMPLETED	2009-08	NCT01224418
DePuy International	—	—	TERMINATED	2018-02-08	NCT01635166
DePuy International	—	—	TERMINATED	2016-01-01	NCT01134445
Amgen	Etanercept	Tumor Necrosis Factor Blocker [EPC]	TERMINATED	2015-06-11	NCT01927757
Roche	Methotrexate (stable dose)	—	TERMINATED	2015-02	NCT01661140
Pfizer	Etanercept	Tumor Necrosis Factor Blocker [EPC]	TERMINATED	2014-08	NCT01783015
Roche	tocilizumab [RoActemra/Actemra]	—	TERMINATED	2013-01	NCT01251120
Roche	tocilizumab [RoActemra/Actemra]	—	TERMINATED	2012-08	NCT01283971
Roche	rituximab [MabThera/Rituxan]	—	TERMINATED	2010-06	NCT01117129
Wyeth is now a wholly owned subsidiary of Pfizer	etanercept (EnbrelTM)	—	TERMINATED	2009-12	NCT00706797
Roche	methotrexate	Folate Analog Metabolic Inhibitor [EPC]	WITHDRAWN	2015-06	NCT01878318
Wyeth is now a wholly owned subsidiary of Pfizer	Etanercept + Methotrexate	—	WITHDRAWN	2010-06	NCT00783536

Showing 100 of 205 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Hangzhou Highlightll Pharmaceutical Co., Ltd	TLL-018	—	RECRUITING	2026-12-31	NCT06887127
mAbxience Research S.L.	MB04 (proposed biosimilar to etanercept)	—	RECRUITING	2025-10	NCT06596772
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-07	NCT05814627
Hangzhou Highlightll Pharmaceutical Co., Ltd	TLL-018	—	ACTIVE NOT RECRUITING	2026-07-31	NCT06020144
Lynk Pharmaceuticals Co., Ltd	LNK01001	—	ACTIVE NOT RECRUITING	2025-08-22	NCT06276998
Biocad	Levilimab	—	ACTIVE NOT RECRUITING	2024-09	NCT05800327
SetPoint Medical Corporation	Conventional Synthetic DMARD	—	ACTIVE NOT RECRUITING	2024-05-16	NCT04539964
Bristol-Myers Squibb	Abatacept	Selective T Cell Costimulation Modulator [EPC]	ACTIVE NOT RECRUITING	2023-06-14	NCT04909801
AbbVie	Adalimumab	TNF	ACTIVE NOT RECRUITING	2017-10-27	NCT02629159
Celltrion	CT-P13 SC Auto-Injector	—	COMPLETED	2025-06-25	NCT06738719
Alfasigma S.p.A.	Filgotinib	—	COMPLETED	2025-05-16	NCT03025308
Alvotech Swiss AG	AVT05 (proposed biosimilar to golimumab)	—	COMPLETED	2024-03-04	NCT05842213
AO GENERIUM	Complarate®	—	COMPLETED	2024-01-05	NCT06475508
Celltrion	CT-P47	—	COMPLETED	2023-06-29	NCT05489224
Taisho Pharmaceutical Co., Ltd.	TS-152	—	COMPLETED	2023-04-28	NCT04077567
Jiangsu HengRui Medicine Co., Ltd.	SHR0302	—	COMPLETED	2023-01-30	NCT04333771
RemeGen Co., Ltd.	RC18 160 mg plus MTX	—	COMPLETED	2022-11-19	NCT03016013
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2022-08-08	NCT03155347
Dr. Reddy's Laboratories Limited	Experimental: Arm A: DRL_RI	—	COMPLETED	2022-01-26	NCT04268771
Zhejiang Hisun Pharmaceutical Co. Ltd.	HS628+MTX	—	COMPLETED	2021-09-14	NCT06048224
R-Pharm International, LLC	Olokizumab 64 mg SC q4w	—	COMPLETED	2021-09-01	NCT03120949
Fresenius Kabi SwissBioSim GmbH	MSB11456	—	COMPLETED	2021-08-31	NCT04512001
Pfizer	PF-06410293	—	COMPLETED	2021-06-22	NCT04230213
Astellas Pharma China, Inc.	Peficitinib	—	COMPLETED	2021-04-01	NCT03660059
Biocad	BCD-089	—	COMPLETED	2021-03-15	NCT04227366
Bio-Thera Solutions	BAT1806	—	COMPLETED	2021-01-05	NCT03830203
Sanofi	SAR153191 (REGN88)	—	COMPLETED	2020-12-31	NCT01146652
Eli Lilly	Baricitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2020-11-12	NCT01885078
Alvotech Swiss AG	—	—	COMPLETED	2020-07-08	NCT04224194
Shanghai Henlius Biotech	HLX01	—	COMPLETED	2020-04-05	NCT03522415
Celltrion	CT-P13	—	COMPLETED	2020-03-16	NCT03707535
Amgen	etanercept pre-filled syringe subcutaneous injection	—	COMPLETED	2019-12-06	NCT02373813
Celltrion	CT-P17 SC AI (adalimumab)	—	COMPLETED	2019-11-04	NCT04171414
Celltrion	CT-P17 SC	—	COMPLETED	2019-10-08	NCT03789292
R-Pharm International, LLC	Olokizumab	—	COMPLETED	2019-09-12	NCT02760433
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2019-08-14	NCT02955212
R-Pharm International, LLC	Olokizumab 64mg q4w	—	COMPLETED	2019-08-02	NCT02760407
Shanghai Biomabs Pharmaceutical Co., Ltd.	CMAB008	—	COMPLETED	2019-06-23	NCT03478111
AbbVie	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2019-06-13	NCT03086343
Nichi-Iko Pharmaceutical Co., Ltd.	NI-071	—	COMPLETED	2019-05-20	NCT02990806
Gilead	Filgotinib	—	COMPLETED	2018-10-05	NCT02886728
R-Pharm International, LLC	Olokizumab	—	COMPLETED	2018-08	NCT02760368
Gilead	Filgotinib	—	COMPLETED	2018-07-04	NCT02889796
UCB Biopharma S.P.R.L.	e-Device	—	COMPLETED	2018-07-02	NCT03357471
Biocad	BCD-055	—	COMPLETED	2018-07	NCT02762838
Fresenius Kabi SwissBioSim GmbH	MSB11022	—	COMPLETED	2018-05-28	NCT03052322
Celltrion	CT-P13	—	COMPLETED	2018-05-21	NCT03147248
Gilead	Filgotinib	—	COMPLETED	2018-03-20	NCT02873936
AbbVie	Methotrexate	Folate Analog Metabolic Inhibitor [EPC]	COMPLETED	2018-03-15	NCT02706873
LG Life Sciences	LBEC0101	—	COMPLETED	2017-12	NCT02715908
AbbVie	Methotrexate	Folate Analog Metabolic Inhibitor [EPC]	COMPLETED	2017-10-02	NCT02706951
Coherus Oncology, Inc.	CHS-0214	—	COMPLETED	2017-09	NCT02486939
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2017-08-03	NCT02720523
Astellas Pharma Inc	Peficitinib	—	COMPLETED	2017-06-20	NCT02305849
Mabion SA	Rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2017-05	NCT02468791
Eli Lilly	Baricitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2017-05	NCT02265705
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2017-04-21	NCT02675426
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2017-04-03	NCT02706847
Pfizer	Tofacitinib	—	COMPLETED	2017-03-15	NCT02281552
Gema Biotech S.A.	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2017-03	NCT03332719
Momenta Pharmaceuticals, Inc.	M923	—	COMPLETED	2017-02-21	NCT02722044
Biocad	Acellbia	—	COMPLETED	2017-02	NCT02744196
Novartis	Adalimumab - GP2017	—	COMPLETED	2017-01-31	NCT02744755
Astellas Pharma Inc	Peficitinib	—	COMPLETED	2017-01-23	NCT02308163
Bristol-Myers Squibb	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2017-01-16	NCT02504268
Novartis	GP2015	—	COMPLETED	2016-12-29	NCT02638259
UCB Pharma SA	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-12	NCT02319642
Korea Otsuka Pharmaceutical Co., Ltd.	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-11	NCT01197066
Sanofi	Sarilumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2016-11	NCT02373202
Roche	Tocilizumab (TCZ)	—	COMPLETED	2016-10-14	NCT01855789
Sanofi	Sarilumab SAR153191 (REGN88)	—	COMPLETED	2016-10	NCT02293902
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2016-10	NCT02011334
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2016-09-13	NCT02046616
Pfizer	PF-06410293	—	COMPLETED	2016-08-31	NCT02480153
Cinnagen	Adalimumab	TNF	COMPLETED	2016-08-17	NCT03172325
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2016-08-04	NCT02046603
Roche	Azathioprine	Purine Antimetabolite [EPC]	COMPLETED	2016-07-10	NCT01941095
Novartis	GP2013 - A Proposed biosimilar rituximab	—	COMPLETED	2016-07	NCT02514772
Pfizer	PF-06438179	—	COMPLETED	2016-06-29	NCT02222493
UCB Pharma SA, Belgium	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-06	NCT02151851
Roche	Non-Biologic DMARDs	—	COMPLETED	2016-05-26	NCT01987479
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2016-05-11	NCT01668966
Sanofi	Sarilumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2016-01-20	NCT02332590
Celltrion	CT-P10	—	COMPLETED	2016-01	NCT02149121
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-12	NCT02001987
Coherus Oncology, Inc.	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2015-10	NCT02115750
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-09-09	NCT01941940
Novartis	Secukinumab (AIN457)	—	COMPLETED	2015-09-09	NCT01377012
Roche	tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-09	NCT02031471
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-09	NCT01734993
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-08	NCT01951170
UCB Pharma	Certolizumab Pegol + Methotrexate (MTX)	—	COMPLETED	2015-07	NCT01521923
Roche	DMARD	—	COMPLETED	2015-07	NCT01995201
Biocad	Rituximab	CD20-directed Cytolytic Antibody [EPC]	COMPLETED	2015-07	NCT01759030
Roche	tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-07	NCT01988012
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-07	NCT01655381
Roche	Tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-06	NCT01664598
Sanofi	sarilumab SAR153191 (REGN88)	—	COMPLETED	2015-05	NCT02121210
Roche	tocilizumab	Interleukin-6 Receptor Antagonist [EPC]	COMPLETED	2015-05	NCT01772316
Roche	tocilizumab [RoActemra/Actemra]	—	COMPLETED	2015-05	NCT01730456

Showing 100 of 246 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Citryll BV	[89Zr]Zr-CIT	—	RECRUITING	2026-10-01	NCT07147959
Spyre Therapeutics, Inc.	SPY002-072	—	RECRUITING	2026-10-31	NCT07148414
Toll Biotech Co. Ltd. (Beijing)	Group 1: TollB-001 100mg qd po; Group 2: TollB-001 200mg qd po; Group 3: TollB-001400mg qd po	—	RECRUITING	2026-12	NCT07408024
Surf Therapeutics	—	—	RECRUITING	2026-12	NCT07293871
AbbVie	Lutikizumab	—	RECRUITING	2027-02	NCT06972446
Citryll BV	CIT-013 low dose	—	RECRUITING	2027-04	NCT06567470
Elevara Medicines Limited	ELV001 25 mg	—	RECRUITING	2027-04-15	NCT07409103
Roche	Afimkibart	—	RECRUITING	2027-04-17	NCT07137598
Avalyn Pharma Inc.	AP01	—	RECRUITING	2027-06	NCT06329401
AstraZeneca	AZD1163	—	RECRUITING	2027-11-12	NCT07276581
Artiva Biotherapeutics, Inc.	Allogeneic NK Cells	—	RECRUITING	2028-01	NCT06991114
Amgen	Inebilizumab	—	RECRUITING	2028-07-21	NCT06570798
Quell Therapeutics Limited	QEL-005	—	RECRUITING	2028-08	NCT07473154
Novartis	Rapcabtagene autoleucel	—	RECRUITING	2028-11-01	NCT07048197
Changchun GeneScience Pharmaceutical Co., Ltd.	GenSci048	—	RECRUITING	2026-03-31	NCT06189495
SynAct Pharma Aps	AP1189, 40 mg	—	RECRUITING	2025-12	NCT06671054
BeiGene	BGB-45035	—	ACTIVE NOT RECRUITING	2026-10-18	NCT07100938
Immunovant Sciences GmbH	IMVT-1402	—	ACTIVE NOT RECRUITING	2027-09	NCT06754462
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-3045 Injection	—	ACTIVE NOT RECRUITING	2026-04-21	NCT07233655
Eli Lilly	LY3871801	—	ACTIVE NOT RECRUITING	2025-12-08	NCT05848258
Eli Lilly	LY3541860	—	ACTIVE NOT RECRUITING	2025-11-10	NCT06859294
Novartis	VAY736 1ml PFS	—	ACTIVE NOT RECRUITING	2025-06-05	NCT06293365
AnaptysBio, Inc.	Rosnilimab	—	ACTIVE NOT RECRUITING	2024-11-29	NCT06041269
Beijing Baylx Biotech Co., Ltd.	hUC-MSC infusion (BC-U001)	—	ACTIVE NOT RECRUITING	2023-07-10	NCT04971980
XBiotech, Inc.	Natrunix 400 mg	—	NOT YET RECRUITING	2027-01-15	NCT06590090
Changchun GeneScience Pharmaceutical Co., Ltd.	GenSci120 150 mg	—	NOT YET RECRUITING	2027-09	NCT07423533
Qilu Pharmaceutical Co., Ltd.	QLS12010	—	NOT YET RECRUITING	2028-03-05	NCT07377773
Celltex Therapeutics Corporation	autologous adipose derived stem cells	—	NOT YET RECRUITING	2024-12	NCT04170426
Sanofi	SAR441566	—	COMPLETED	2025-06-18	NCT06073093
XBiotech, Inc.	Natrunix	—	COMPLETED	2024-10-31	NCT05363891
Celon Pharma SA	CPL409116	—	COMPLETED	2024-05-27	NCT05374785
Modern Biosciences Ltd	MBS2320 5 mg	—	COMPLETED	2023-12-28	NCT05460832
Aclaris Therapeutics, Inc.	ATI-450 50 mg oral tablet BID	—	COMPLETED	2023-09-05	NCT05279417
SynAct Pharma Aps	AP1189, 60 mg	—	COMPLETED	2023-08-28	NCT05604885
SynAct Pharma Aps	100 mg AP1189	—	COMPLETED	2023-07-20	NCT05516979
Tianjin Hemay Pharmaceutical Co., Ltd	Hemay007 800 mg QD group	—	COMPLETED	2023-06-22	NCT05247216
Beijing VDJBio Co., LTD.	Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection	—	COMPLETED	2023-06-02	NCT05957107
Abivax S.A.	ABX464	—	COMPLETED	2023-01-23	NCT04049448
Galapagos NV	Filgotinib	—	COMPLETED	2023-01-19	NCT02065700
Lynk Pharmaceuticals Co., Ltd	LNK01001 Dose A	—	COMPLETED	2022-12-29	NCT06099535
Hangzhou Highlightll Pharmaceutical Co., Ltd	TLL-018	—	COMPLETED	2022-12-19	NCT05133297
Bristol-Myers Squibb	branebrutinib	—	COMPLETED	2022-12-05	NCT04186871
Jiangsu Alphamab Biopharmaceuticals Co., Ltd	KN019, 5mg/kg	—	COMPLETED	2022-07-28	NCT04038970
Pfizer	PF-06650833	—	COMPLETED	2022-02-07	NCT04413617
Navidea Biopharmaceuticals	Tc99m tilmanocept	—	COMPLETED	2022-01-21	NCT04947137
Eli Lilly	LY3462817	—	COMPLETED	2022-01-10	NCT04634253
Amgen	VIB4920	—	COMPLETED	2021-12-28	NCT04163991
SynAct Pharma Aps	50 mg AP1189	—	COMPLETED	2021-11-16	NCT04004429
Kang Stem Biotech Co., Ltd.	FURESTEM-RA Inj	—	COMPLETED	2021-10-05	NCT03618784
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2021-07-29	NCT02049138
Abivax S.A.	ABX464 50mg	—	COMPLETED	2021-04-27	NCT03813199
Galapagos NV	GLPG3970	—	COMPLETED	2021-03-26	NCT04577781
Navidea Biopharmaceuticals	Tc 99m tilmanocept	—	COMPLETED	2021-02-08	NCT03938636
Aclaris Therapeutics, Inc.	ATI-450	—	COMPLETED	2021-02-04	NCT04247815
Oscotec Inc.	SKI-O-703	—	COMPLETED	2020-10-13	NCT04057118
Hope Biosciences LLC	HB-adMSCs	—	COMPLETED	2020-08-17	NCT03691909
Galapagos NV	Filgotinib	—	COMPLETED	2020-08-14	NCT03926195
AbbVie	ABBV-3373	—	COMPLETED	2020-04-08	NCT03823391
AbbVie	Elsubrutinib	—	COMPLETED	2020-03-26	NCT03682705
Taiho Pharmaceutical Co., Ltd.	TAS5315 low dose	—	COMPLETED	2019-11-30	NCT03605251
Yungjin Pharm. Co., Ltd.	YRA-1909 low dose	—	COMPLETED	2019-11-19	NCT03275025
AstraZeneca	AZD9567	—	COMPLETED	2019-11-12	NCT03368235
Chong Kun Dang Pharmaceutical	CKD-506	—	COMPLETED	2019-09-30	NCT04204603
EMD Serono Research & Development Institute, Inc.	M2591 25 mg QD	—	COMPLETED	2019-09-23	NCT03233230
Roche	GDC-0853	—	COMPLETED	2019-07-17	NCT02983227
Jiangsu HengRui Medicine Co., Ltd.	SHR0302	—	COMPLETED	2019-04-16	NCT03254966
Rottapharm Biotech	CR6086	—	COMPLETED	2019-01-08	NCT03163966
Modern Biosciences Ltd	MBS2320	—	COMPLETED	2018-11-16	NCT03139136
Astellas Pharma Inc	ASP5094	—	COMPLETED	2018-09-19	NCT03257852
Pfizer	PF-06650833	—	COMPLETED	2018-08-15	NCT02996500
Shanghai Henlius Biotech	HLX01	—	COMPLETED	2018-08	NCT03355872
Ablynx, a Sanofi company	ALX-0061	—	COMPLETED	2018-08	NCT02518620
Roche	GDC-0853	—	COMPLETED	2018-07-02	NCT02833350
Akros Pharma Inc.	JTE-051	—	COMPLETED	2018-06-25	NCT02919475
Light Chain Bioscience - Novimmune SA	NI-0101	—	COMPLETED	2018-06-20	NCT03241108
Eisai Co., Ltd.	E6011	—	COMPLETED	2018-05-16	NCT02960490
Bristol-Myers Squibb	BMS-986142	—	COMPLETED	2018-05-03	NCT02638948
Eisai Co., Ltd.	E6011	—	COMPLETED	2018-02-28	NCT02960438
Pfizer	PF-06651600	—	COMPLETED	2017-12-12	NCT02969044
Astellas Pharma Inc	ASP1707	—	COMPLETED	2017-10-18	NCT02884635
Gilead	GS-9876	—	COMPLETED	2017-08-22	NCT02885181
Samsung Bioepis Co., Ltd.	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2017-08-03	NCT03193957
EMD Serono Research & Development Institute, Inc.	M2951	—	COMPLETED	2017-04-30	NCT02784106
UCB Celltech	Bimekizumab	—	COMPLETED	2017-04	NCT02430909
Bausch Health Americas, Inc.	SAN-300 0.5 mg/kg QW	—	COMPLETED	2017-02-23	NCT02047604
Dr. Reddy's Laboratories Limited	DRL_RI	—	COMPLETED	2016-11	NCT02296775
Ablynx, a Sanofi company	ALX-0061	—	COMPLETED	2016-08	NCT02309359
Ablynx, a Sanofi company	ALX-0061	—	COMPLETED	2016-07	NCT02287922
Takeda	Namilumab	—	COMPLETED	2016-05-11	NCT02379091
Mesoblast, Ltd.	Allogeneic Mesenchymal Precursor Cells	—	COMPLETED	2016-05	NCT01851070
Acerta Pharma BV	acalabrutinib	—	COMPLETED	2016-05	NCT02387762
AbbVie	ABT-122	—	COMPLETED	2016-05	NCT02433340
Samsung Bioepis Co., Ltd.	Adalimumab PFS and Pen	—	COMPLETED	2016-03	NCT02565810
SinoMab BioScience Ltd	SM03	—	COMPLETED	2016-02-03	NCT04192617
Novartis	GP2013	—	COMPLETED	2016-01	NCT01274182
Bristol-Myers Squibb	CC-292	—	COMPLETED	2016-01	NCT01975610
Theramab LLC	TAB08	—	COMPLETED	2015-12	NCT01990157
AbbVie	adalimumab	TNF	COMPLETED	2015-09	NCT02141997
Maoxiang Group Jilin Pharmaceutical Co., Ltd.	Fang yi qing feng shi granule	—	COMPLETED	2015-08	NCT02029599
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2015-07-02	NCT02066389

Showing 100 of 194 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Changchun GeneScience Pharmaceutical Co., Ltd.	GenSci120	—	RECRUITING	2026-07-05	NCT07040930
Sonoma Biotherapeutics, Inc.	SBT777101	—	RECRUITING	2026-11	NCT06201416
Kali Therapeutics, Inc.	KT501	—	RECRUITING	2027-02	NCT07234773
Gilead	GS-0151	—	RECRUITING	2027-03	NCT06902519
Adicet Therapeutics	ADI-001	—	RECRUITING	2027-03-30	NCT07100873
AstraZeneca	AZD5492	—	RECRUITING	2027-05-05	NCT06916806
Bristol-Myers Squibb	BMS-986454	—	RECRUITING	2027-06-28	NCT07171983
Lifordi Immunotherapeutics, Inc.	LFD-200	—	RECRUITING	2027-07-16	NCT07207954
Capstan Therapeutics	CPTX2309	—	RECRUITING	2027-11	NCT06917742
Sichuan Baili Pharmaceutical Co., Ltd.	GNC-038	—	RECRUITING	2027-12	NCT06857227
Cullinan Therapeutics Inc.	CLN-978	—	RECRUITING	2027-12-30	NCT06994143
Shenzhen MagicRNA Biotechnology Co., Ltd	HN2301 injection	—	RECRUITING	2027-12-31	NCT06801119
AstraZeneca	AZD0120	—	RECRUITING	2028-02-22	NCT07295847
SciRhom GmbH	SR-878	—	RECRUITING	2028-02-29	NCT07433335
Eli Lilly	LY4213663	—	RECRUITING	2028-03	NCT07258849
Eli Lilly	LY4298445	—	RECRUITING	2028-03	NCT07276958
Novartis	PIT565	—	RECRUITING	2028-05-15	NCT07029555
Xencor, Inc.	Plamotamab	—	RECRUITING	2028-06	NCT07230353
AstraZeneca	Surovatamig	—	RECRUITING	2028-06-27	NCT07201558
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	CC-97540	—	RECRUITING	2028-08-29	NCT05869955
Philogen S.p.A.	F8IL10	—	RECRUITING	2028-09-30	NCT07245992
Sanofi	SAR448501	—	RECRUITING	2029-06-25	NCT06647069
Merck	MK-1045	—	RECRUITING	2029-07-16	NCT07363590
China Immunotech (Beijing) Biotechnology Co., Ltd.	YTS109 cell	—	RECRUITING	2026-05-19	NCT06978647
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-3045 Injection	—	RECRUITING	2026-03	NCT07200596
LAPIX Therapeutics Inc.	LPX-TI641	—	RECRUITING	2025-12-15	NCT06628206
Shanghai Qilu Pharmaceutical Research and Development Center LTD	QLS12010	—	RECRUITING	2025-12	NCT06946641
ILAb Co., Ltd.	IA-14069	—	RECRUITING	2025-11	NCT05533372
Zenas BioPharma (USA), LLC	ZB002	—	RECRUITING	2025-07	NCT05638854
Candid Therapeutics	CND261	—	ACTIVE NOT RECRUITING	2027-06-01	NCT07052032
Gilead	GS-0272	—	ACTIVE NOT RECRUITING	2026-05	NCT06031415
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-3045 Injection	—	ACTIVE NOT RECRUITING	2025-06-17	NCT06883695
Mabscale, LLC	Rituximab	CD20-directed Cytolytic Antibody [EPC]	ACTIVE NOT RECRUITING	2024-11	NCT06175338
Seismic Therapeutic AU Pty Ltd	S-4321	—	NOT YET RECRUITING	2027-06	NCT07455578
Kali Therapeutics, Inc.	KT502	—	NOT YET RECRUITING	2027-12	NCT07564154
Baylx Inc.	hUC-MSC suspension	—	NOT YET RECRUITING	2027-12-31	NCT03828344
Neutrolis	NTR1011	—	COMPLETED	2026-02-17	NCT07237659
AstraZeneca	AZD6912	—	COMPLETED	2025-10-16	NCT06115967
Artivila (Shenzhen) Innovation Center, Ltd	ARD-885 Tablets	—	COMPLETED	2025-08-14	NCT07266207
Shanghai Kanda Biotechnology Co., Ltd.	KD6005	—	COMPLETED	2025-01-10	NCT06213259
Lipum AB	SOL-116	—	COMPLETED	2024-11-28	NCT05576012
Kashiv BioSciences, LLC	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2024-10-16	NCT06929039
Novartis	ianalumab	—	COMPLETED	2024-07-18	NCT03574545
Chengdu Zenitar Biomedical Technology Co., Ltd	ZL-82 12.5mg	—	COMPLETED	2024-01-28	NCT06055023
Jiangsu vcare pharmaceutical technology co., LTD	VC005 tablets	—	COMPLETED	2023-10-18	NCT05874622
Sanofi	SAR441566	—	COMPLETED	2023-10-15	NCT05844735
Teijin America, Inc.	TCK-276	—	COMPLETED	2023-07-20	NCT05437419
Sanofi	SAR441566	—	COMPLETED	2023-07-17	NCT05858788
UCB Biopharma SRL	Pharmacokinetics of certolizumab pegol	—	COMPLETED	2023-05-23	NCT04163016
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQH3821 tablets	—	COMPLETED	2023-05-20	NCT05380934
Johnson & Johnson	JNJ-67484703	—	COMPLETED	2023-05-18	NCT04985812
Jiangsu HengRui Medicine Co., Ltd.	SHR0302 Tablets	—	COMPLETED	2022-08-18	NCT05392127
Jiangsu HengRui Medicine Co., Ltd.	itraconazole、 SHR0302 tablets	—	COMPLETED	2022-07-11	NCT05404724
R-Pharm International, LLC	Olokizumab	—	COMPLETED	2022-06-08	NCT04246762
LISCure Biosciences	LB-P6	—	COMPLETED	2022-04-01	NCT05053165
Longevity Inc.	Proximod	—	COMPLETED	2022-02-16	NCT06361199
Pfizer	PF-06835375	—	COMPLETED	2022-02-15	NCT03334851
UCB Biopharma SRL	Certolizumab pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2022-01-24	NCT04740814
Beijing VDJBio Co., LTD.	IL-6R Monoclonal Antibody Injection 4mg/kg	—	COMPLETED	2021-10-27	NCT05232396
Oryn Therapeutics, LLC	Low dose ORTD-1	—	COMPLETED	2021-10-12	NCT04286789
Jiangsu HengRui Medicine Co., Ltd.	SHR0302、[14C]SHR0302	—	COMPLETED	2021-09-19	NCT05047341
Gilead	Atorvastatin	—	COMPLETED	2021-01-13	NCT04608344
Daewon Pharmaceutical Co., Ltd.	DW1809-T2	—	COMPLETED	2020-09-08	NCT05214690
Daewon Pharmaceutical Co., Ltd.	DW1809	—	COMPLETED	2020-09-07	NCT05214677
Taizhou Mabtech Pharmaceutical Co.,Ltd	Infliximab	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2020-06-15	NCT04779892
Fountain Biopharma Inc.	FB704A	—	COMPLETED	2020-05-27	NCT03890302
Fresenius Kabi SwissBioSim GmbH	40 mg MSB11022	—	COMPLETED	2020-03-17	NCT04018599
Amgen	Rozibafusp Alfa	—	COMPLETED	2019-10-17	NCT03156023
Bio-Thera Solutions	BAT1806 injection	—	COMPLETED	2019-07-17	NCT03606876
Chong Kun Dang Pharmaceutical	D569 Tab.	—	COMPLETED	2019-04-05	NCT03858725
Bristol-Myers Squibb	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2019-04-02	NCT03714022
Chong Kun Dang Pharmaceutical	XELJANZ 5Mg Tablet	—	COMPLETED	2019-03-29	NCT03868072
Boryung Pharmaceutical Co., Ltd	BR9001	—	COMPLETED	2019-03-18	NCT03718611
Gilead	Filgotinib	—	COMPLETED	2018-08-09	NCT03417778
Amgen	VIB4920	—	COMPLETED	2018-05-21	NCT02780388
Archigen Biotech Limited	SAIT101	—	COMPLETED	2018-04-30	NCT02819726
Hanlim Pharm. Co., Ltd.	HL237	—	COMPLETED	2018-03-19	NCT03278470
Innocare Pharma Australia Pty Ltd	ICP-022	—	COMPLETED	2018-02-05	NCT03189017
Novartis	VAY736	—	COMPLETED	2018-01-22	NCT02675803
Bristol-Myers Squibb	BMS-986195	—	COMPLETED	2017-12-19	NCT03262740
Bristol-Myers Squibb	BMS-986195	—	COMPLETED	2017-11-05	NCT03131973
Longevity Inc.	Proximod	—	COMPLETED	2017-11-01	NCT06361186
Bristol-Myers Squibb	BMS-986195	—	COMPLETED	2017-09-22	NCT03245515
AstraZeneca	AZD9567 10 mg	—	COMPLETED	2017-09-11	NCT02760316
Astellas Pharma Global Development, Inc.	ASP5094	—	COMPLETED	2017-09-07	NCT02698657
Bristol-Myers Squibb	BMS-986195	—	COMPLETED	2017-08-16	NCT02705989
Philogen S.p.A.	F8IL10	—	COMPLETED	2017-04	NCT02076659
Novartis	CFZ533	—	COMPLETED	2017-02-03	NCT02089087
Navidea Biopharmaceuticals	Tilmanocept	—	COMPLETED	2016-12	NCT02683421
UCB BIOSCIENCES, Inc.	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-10	NCT02019602
AstraZeneca	AZD9567 Monohydrat	—	COMPLETED	2016-09-26	NCT02512575
Gilead	Tirabrutinib	—	COMPLETED	2016-09-01	NCT02626026
Astellas Pharma Global Development, Inc.	ASP1707	—	COMPLETED	2016-08-30	NCT02867306
Bristol-Myers Squibb	BMS-986142 200mg	—	COMPLETED	2016-08	NCT02762123
OSE Immunotherapeutics	FR104	—	COMPLETED	2016-06	NCT02800811
Takeda	—	—	COMPLETED	2016-04-05	NCT02528786
Oscotec Inc.	SKI-O-703 capsule	—	COMPLETED	2016-03	NCT02717988
Sanofi	sarilumab SAR153191 (REGN88)	—	COMPLETED	2016-03	NCT02017639
Sanofi	sarilumab SAR153191 (REGN88)	—	COMPLETED	2016-03	NCT02404558
AbbVie	ABBV-257	—	COMPLETED	2016-02	NCT02531178

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Rheumatoid Arthritis

TNF-alpha (20)

Novel Drugs by Company (New molecular entities)

Johnson & Johnson 3 drugs

Amgen 3 drugs

Roche 2 drugs

CELLTRION INC 2 drugs

Fresenius Kabi 2 drugs

IMMUNEX 1 drug

AbbVie 1 drug

UCB INC 1 drug

Sanofi 1 drug

Viatris 1 drug

+11 more companies

Reformulations (25 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.